Inhibitor of growth 4 (ING4), a member of the conserved ING family, has been identified as an important tumor suppressor since it plays a critical role in the regulation of chromatin modification, cell proliferation, angiogenesis and cell migration. Some observations suggest that ING4 acts as a key regulator of tumorigenesis through modifying gene transcription in part by regulating the transcription factors p53 and NF-kappaB (NF-κB). However, these models have yet to be substantiated by further investigations. Numerous reports describe the reduced expression of ING4 in cancers, and the responsible mechanisms are involved in gene deletion, mutation, transcriptional and post-transcriptional dysregulation. This review aims to summarize the recent published literature that investigates the role of ING4 in regulating tumorigenesis and progression, and explore its potential for cancer treatment.
Introduction
Inhibitor of growth (ING) family proteins are evolutionary conserved in all eukaryotes and have been regarded as important tumor suppressors. Comparison to genomes of other organisms revealed that the ING family is highly conserved from yeast to humans, suggesting it is involved in critical biological processes [1] . In human and mouse, it consists of five members, namely ING1 to 5. In yeast, Yng1, Yng2, and PHO23 are identified as three ING orthologues [2] . ING1 was first identified as a candidate tumor suppressor in subtractive
Genomic Organization
ING family consists of five members, some of which harbor several exons and therefore can be alternatively spliced into different splice variants, conferring more diversity to ING family functions. The five ING genes are located on five different chromosomes, and they are all close to the telomere/subtelomere region except ING3. The ING4 gene is located at chromosome 12p13.31. The original ING4 (ING4_v1) was identified by computational homology search and eight splice variants of ING4 have been discovered so far [13] [14] [15] . However, the roles of each endogenous variant are still unclear. ING4_v1 encodes a complete nuclear localization signal (NLS), whereas the ING4_v2 (a 3-bp skip form), ING4_v3 (a 9-bp skip form), and ING4_v4 (a 12-bp skip form) lack 1, 3, and 4 amino acids in the NLS, resulting in increased cytoplasmic localization of these proteins [13, 16, 17] (Fig. 1) . The ING4_v4 lacking of four amino acids (KGKK) was initially regarded as genomic deletions in human cancer cell lines [18] , but now it is now accepted that it represents a natural splicing variant [13, 14] . Additional four novel ING4 variants respectively lacking exons 2, 3 and 6 are named ING4-ΔEx2, -ΔEx3, -ΔEx6A and -ΔEx6B [14] .
Protein Structure
ING proteins contain several highly conserved regions, and many of them have been shown to be essential for ING proteins functions. The plant homeodomain (PHD)-like zincfinger domain is the most conserved region located in the C-terminus of ING proteins, which has been implicated in chromatin remodeling through interacting with specific nuclear protein partners [19] . Moreover, the PHD finger of ING proteins has been found to bind to H3K4me3 (the trimethylated lysine 4 residue of histone H3) [20, 21] , a hallmark of active genes preferentially in sharp peaks at or immediately upstream of transcription start sites (TSS) [22] , supporting the role of ING proteins in regulating chromatin structure and controlling transcriptional activity.
The nuclear localization sequence (NLS) is also a highly conserved region located upstream of the PHD. The nucleolar targeting signals (NTS) within the NLS mediated localization of p33ING1b to the nucleolus in response to UV-induced DNA damage [23] . However, the NTS motifs are not complete in ING3 to ING5 [1] , suggesting the ability of nucleolus targeting may be compromised in these isoforms. In addition, NLS is also essential for ING4 nuclear localization and interaction with p53 [16] . [40, 41] . Allelic loss of ING4 locus has been frequently found in head and neck squamous cell carcinomas and in breast tumors [18, 27] . In addition, point mutations of ING4 also contribute to the loss of ING4 function and tumorigenesis. The N214D mutant attenuated the ING4-mediated inhibition of cell proliferation, anchorageindependent growth, migration and induction of cell death, probably because the N214 residue is located in the conserved PHD domain, which is required for the recognition of H3K4me3 [42] . Interestingly, the altered ratio of nuclear and cytoplasmic ING4 expression [43] . ING4 loss was required for Mycdependent prostate tumorigenesis in mice. Also, Pten loss could prevent differentiation by blocking ING4 expression [44] . In addition, cDNA Microarrays showed that ING4 was responsible to the human runt-related transcription factor 3 gene (RUNX3) upregulation in gastric cancer cells, but the molecular mechanisms was still unknown [45] .
Post-transcriptional regulation also play important role in ING4 down-expression. Altered expression or mutation of splicing factors may cause a shift in the ratio of alternatively spliced isoforms, altering the ING4 splicing profiling of cancer cells. Raho et al. discovered four ING4 variants designated as ING4-ΔEx2, -ΔEx3, -ΔEx6A and -ΔEx6B in both normal and tumor tissues, which retained the nuclear localization and the ability to interact with p53 and HBO1 complex. However, the ING4-ΔEx6A variant, devoid of the C-terminal portion, lost the capability to inhibit NF-κB [14] . Li et al. also identified five novel aberrantly spliced variant forms of ING4_v1 and ING4_v2 which caused a deletion of the NLS or PHD domain contributing to the mislocalization of p53 and/or HAT/HDAC complexes in gastric adenocarcinoma [28] . Furthermore, accumulating evidence shows that microRNA (miRNA) represents an important post-transcriptional regulation mechanism for the inactivation of ING4 genes. For example, miR-214 promoted survival as well as gemcitabine resistance of pancreatic cancer cells partly through targeting ING4 [46] . MiR-650 has been reported to regulate ING4 in various cancers, including gastric, lung, hepatocellular and leukemic cancer cells [47] [48] [49] . Our previous work demonstrated that miR-650 conferred the docetaxel chemoresistance of lung adenocarcinoma (LAD) cells through directly targeting ING4, leading to increased cell apoptosis via regulating Bcl-2/Bax expression. Furthermore, miR-650 expression was negatively correlated with response of LAD patients to docetaxel and served as an independent prognostic factor for LAD patients [50] .
Tumor suppressive functions
Abundant evidence has supported the tumor suppressor role of ING proteins since their discovery. Interestingly, ING1 and ING2, ING4 and ING5 are respectively closely related in evolution and structure, indicating that they may have similar or complementary functions [1] . ING4 shares the capacity of chromatin modification and cell proliferation inhibition with other ING proteins, while it is worth highlighting its unique role in the regulation of angiogenesis and cell migration.
Chromatin remodeling ING family proteins are involved in chromatin remodeling through interaction with histone modifiers such as histone acetyl transferase (HAT) and histone deacetylase (HDAC) complexes. For example, ING1 and ING2 are stable components of mSin3 HDAC complexes [51] . ING3 is a subunit of the Tip60/NuA4 HAT complexes [52] . ING5 associates with two distinct complexes containing HBO1 or nucleosomal H3-specific MOZ/MORF HATs [52] . ING4 is required for the HBO1/JADE histone acetyltransferases (HAT) to increase histone acetylation [52] . HBO1 and ING4 were bridged by Bromodomain-containing protein 1 (BRD1), a subunit of the MOZ/MORF H3 HAT, and the HBO1-BRD1-ING4 complex was crucial for transcriptional activation of erythroid developmental regulator genes [53] . Like other members of ING family, it directed these histone acetylation complexes to specific regions of the chromatin, through recognition of H3K4me3 via the highly conserved PHD finger [ 54] . The interaction between ING4 and H3K4me3 promoted HBO1 acetylation of histone H3, which was required for ING4-mediated cell death and inhibition of anchorage-independent growth [55] . ING4 have been described to associate with p53, the p65 subunit of the transcription factor NF-κB and the hypoxia-inducible factor proly l hydroxylase 2 (HPH-2), resulting in enhancement of p53 transcriptional activity and repression of NF-κB and HIF responsive genes [7, [56] [57] [58] . These reports all point to an ING4 function model that ING4 may serve as a bridge to bring histone-modifying complexes to particular genomic regions by binding to specific DNA-binding proteins in response to various stresses, thus linking ING4 to chromatin remodeling function and gene expression regulation (Fig. 2B) .
Cell proliferation
ING4 overexpression could suppress cell proliferation, induce cell cycle arrest and apoptosis, and enhance chemosensitivity in various cancers [7, [59] [60] [61] [62] [63] [64] [65] [66] . An oncolytic HSV1716 that expresses ING4 (HSV1716Ing4) showed stronger oncolytic effect than HSV1716, highlighting the potent tumor-destructive ability of ING4 [67] . This anti-proliferation capacity is p53-dependent at least in part. ING4 and ING5 could increase p53 acetylation at lys-382 residue by interacting with p300, a component of HAT complexes, leading to p21/ WAF1 transcriptional activation and cell proliferation suppression, cell cycle arrest and apoptosis [7] . In glioma, curcumin was identified as an upstream regulator of ING4, inducing G2/M cell cycle arrest in a p53-dependent manner [68] . Interestingly, Epstein-Barr virus (EBV)-encoded EBNA3C, an essential transcriptional regulator for transforming primary B cells, could compete for the binding regions of ING4 with p53, thus blocking ING4-mediated p53 transcriptional activity and cell proliferation inhibition, suggesting ING4 was a possible target for some oncogenic viruses [69] . A recent research discovered that ING4 could regulate the proliferation and the secretory phenotype of primary non-transformed human fibroblasts, thus playing a critical role in the non-cell-autonomous regulation of tumor growth [62] .
In addition, ING4 was shown to block Myc-induced loss of contact inhibition and breast cancer cells growth in vitro and in vivo, and the ING4 mutant exacerbated Myc-initiated mammary tumorigenesis by decreasing apoptosis and increasing metastasis, suggesting ING4 functioned to suppress Myc [18, 70] . ING4 might abolish the Myc translation and cell proliferation through interaction with a ribonucleoprotein AUF1 (AU-rich RNA-binding factor 1) [71] . In turn, ING4 could serve as a downstream modulator of Myc and PTEN in human prostate epithelial differentiation. PTEN-mediated loss of ING4 altered differentiation and promoted Myc-driven oncogenesis [44] .
A recent research discovered that autophagy also contributed to ING4-induced glioma cell death in addition to apoptosis pathway [72] . Autophagy is an evolutionarily conserved process whereby the unnecessary or dysfunctional cellular components are degraded and recycled through the actions of lysosomes in responsive to cell nutritional starvation and other stressful stimuli. Basically, autophagy has been considered as an adaptive response to stress that sustains survival, whereas in some cases it can also lead to cell death and therefore is called Type II program cell death [73] .
Angiogenesis
Reduced expression of ING4 in a mouse xenograft model of human glioblastoma cells could promote cancer cells grow and angiogenesis, suggesting that ING4 may act as a repressor of angiogenesis [56] . The correlation between ING4 and angiogenesis has been further confirmed in various cancers including ovarian cancer, colon cancer and breast cancer [74] [75] [76] [77] . These functions depended on the interaction between ING4 and the nuclear factor NF-κB in glioblastoma cells. ING4 could decrease NF-κB binding activity as well as transcriptionally repress NF-κB-responsive genes, including IL-8, IL-6, COX-2, CSF-3 and many angiogenesis-related genes [56] . NF-κB is constitutively activated in many cancers and shown to facilitate tumorigenesis. Therefore, the suppression of NF-κB signaling pathway by ING4 indicates that ING4 is a candidate tumor suppressor and that its absence in tumors may allow inappropriately activation of NF-κB signaling and contribute to tumor growth. Nozell et al. further confirmed that ING4 could attenuate NF-κB activity at the target gene promoters through reducing p65 phosphorylation and the p65-p300 interactions to favor the p65-HDAC-1 interactions [78] . Macrophages isolated from ING4-null mice have reduced IκB levels and increased nuclear RelA levels and NF-κB promoter binding [79] . Hou et al. also found that ING4 could act as an E3 ubiquitin ligase to induce ubiquitination and degradation of p65, which is an additional mechanism to link ING4 to NF-κB [80] . In addition, ING4 was the upstream regulator of JWA, activating JWA promoter, inhibiting ILK and downstream NF-κB/IL-6/STAT3/VEGF signaling pathways, thus promoting melanoma angiogenesis [81] . In melanoma, ING4 was induced by BRMS1 (Breast cancer metastasis suppressor 1), a metastasis suppressor, and regulated angiogenesis through inhibiting NF-κB activity and IL-6 level [82] .
In addition to NF-κB, an interaction between ING4 and hypoxia inducible factor (HIF) has also been described, which played a key role in ING4-mediated suppression of MMinduced angiogenesis. ING4 was recruited by the HIF-1-regulating key molecule HIF proly l hydroxylase 2 (HPH-2) to HIF under hypoxic conditions, acting as a suppressor of HIF activity [57, 58, 83] . Evidence supports that ING4's mode of action in regulating HIF is also depend on its ability to recruit chromatin-remodeling factors [58] . However, further studies will be required to clarify the precise mechanism.
Cell migration ING4 has also been linked to the suppression of cell spreading, cell migration and contact inhibition. Li et al. found that ING4 expression was correlated with melanoma thickness, ulceration, as well as 5-year survival of patients with primary melanoma. In addition, ING4 overexpression could inhibit melanoma cell invasion through suppressing the activity of the small GTPase RhoA, the Rho kinase ROCK as well as MMP-2 and MMP-9 [84] . Many of these invasion-related genes such as MMPs are known to be regulated by NF-κB [85] . A significant negative correlation between expression of nuclear p65, MMP-9 and ING4 was observed in human astrocytomas, and the reduction of ING4 expression was related to higher histologic grades [31] . ING4 could repress the expression of NF-κB-target genes including IL6, IL8, and PTGS2, leading to attenuated cell migration in breast cancer cells [37] . Similarly, adenovirus-mediated ING4 expression contributed to suppression of lung carcinoma cell invasion and metastasis [86] . In addition, Shen et al. demonstrated that liprin ɑ1/PPFIA1, a cytoplasmic protein necessary for focal adhesion formation and axon guidance, was required for ING4-mediated regulation of cell migration, thus increasing our knowledge on the function of cytoplasmic ING4 [87] . However, ING4 variants seemed to have different effect of cell migration suppression and different binding affinities to liprin ɑ1 and G3BP2a [13] . Recently, ING4 has been proposed to mediate the regulation of melanoma cells migration by KAI/CD82 transmembrane protein [88] .
ING4 in cancer therapy
Gene therapy has emerged as a novel promising cancer therapy in recent years. Furthermore, gene therapy combined with conventional anti-cancer strategies has been explored to achieve greater therapeutic benefit while reducing the treatment toxicity and resistance. Since ING4 has been demonstrated to play an important role in suppression of tumorigenesis, it is considered a valuable target for molecular therapy alone or combined with radio-or chemotherapy. Adenovirus-mediated ING4 (Ad-ING4) gene transfer could induce growth inhibition and apoptosis in human lung, pancreatic and breast cancer cells [60, 86, 89] . Furthermore, Ad-ING4 plus cisplatin combined treatment resulted in synergistic growth inhibition, enhanced apoptosis and reduced tumor vessel CD34 expression and microvessel density (MVD) in hepatocarcinoma cells [90] . This combined treatment could also reverse multidrug resistance and induce apoptosis of cisplatin-resistant gastric cancer cells in vitro and in vivo [91] . ING4 was also involved in the regulation of docetaxel (DTX) sensitivity in human lung adenocarcinoma (LAD). The molecular mechanism was associated with ING4-induced apoptosis enhancement and G2/M arrest, and miR-650 was identified as its upstream regulator. Furthermore, ING4 expression was inversely correlated with miR-650, and both of their expression levels were correlated with tumor response to DTX and the prognosis of LAD patients [50, 92] . These results have underlined ING4 is a potential molecular target for overcoming resistance to DTX-based chemotherapies in LAD.
Radiotherapy is also an effective measures commonly used for cancer treatment, but the normal tissue radiation injury and the radioresistance remain major challenges that limit its clinical application [93] . Gene therapy can improve the effect of radiation therapy by increasing the cytotoxicity that selectively targets cancer cells and enhancing the radiosensitivity of cancer cells [94] . Therefore, targeting gene therapy combined with radiotherapy has become a novel mode of cancer therapy. Ad-ING4 combined with (125) I radiotherapy treatment had a synergistic tumor-suppressive effect by inducing apoptosis and inhibiting proliferation in pancreatic cancer cells, and inhibiting angiogenesis in pancreatic cancer xenografted tumors [95] . It could also restore the radiosensitivity of NSCLC cells [96] . Extensive studies have shown that IL-24 displays ubiquitous antitumor property and tumor-specific killing activity [97] . ING4/IL-24 bicistronic adenovirus (Ad-ING4-IL-24) combination treatment was shown to have a synergistic tumor-suppressive capacity in NSCLC, breast cancer and hepatocarcinoma and promote radiosensitivity of breast cancer cells [98] [99] [100] [101] . 
Conclusion and future directions
Although ING4 has not been identified until very recent years, it has emerged to be a potent tumor suppressor of ING family. ING4 can regulate chromatin modification through their interaction with HAT or HDAC. It can also significantly suppress tumor growth through inducing apoptosis and cell cycle arrest. In addition, it has been proposed to inhibit tumor angiogenesis and cell migration. Evidence has shown that the ING4 functions are mediated by some important signaling pathways such as p53, NF-κB and HIF-1. However, other candidate mechanisms are also described to be involved in ING4-mediated suppression of tumorigenesis. Therefore, further studies are still warranted to better dissect the mechanisms by which ING4 exerts its functions. Alterations in protein levels or localization of ING4 have been commonly observed in cancers, which contribute to tumor progression and poor prognosis, but little is known about the underlying mechanisms. Given that recent work has substantiated the role of ING4 as a potent tumor suppressor, the ING4-based gene therapy has been developed. Adenovirus-mediated ING4 reintroduction has been shown to inhibit tumor growth, invasion and angiogenesis. When combined with radiation or specific chemotherapy, ING4 can also enhance the radio-and chemosensitivity of cancer cells. Therefore, ING4-based gene therapy represents a promising strategy, but its clinical application still needs further investigations.
